

Resubmission

laronidase (Aldurazyme)

(No: 100/04)

Genzyme

Summary of Advice

13 December 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a resubmission.

Laronidase is not recommended for use within NHS Scotland for the treatment of mucopolysaccharidosis I. Laronidase was approved by the EMEA under exceptional circumstances and has been granted orphan drug status. No information is presented in the submission to support the therapy being cost effective.

Professor David H Lawson
Chairman